205 results on '"BRAF-mutated melanoma"'
Search Results
2. New Melanoma Study Findings Have Been Reported by Investigators at University of Montpellier (Efficiency and Tolerance of Second-line Triple Braf Inhibitor/mek Inhibitor/anti-pd1 Combined Therapy In Braf Mutated Melanoma Patients With Central ...)
3. Research on Apoptosis Published by Researchers at Ruhr-University Bochum (In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes)
4. Study Findings on Melanoma Discussed by Researchers at French National Institute of Health and Medical Research (INSERM) (TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro)
5. Oncology Department Researchers Yield New Study Findings on Personalized Medicine (Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective)
6. Practice Changing Study Highlights Value of Starting Immunotherapy Before Targeted Therapies in Patients with BRAF-Mutated Melanoma
7. Practice Changing Study Highlights Value of Starting Immunotherapy Before Targeted Therapies in Patients with BRAF-Mutated Melanoma
8. Research Conducted at University of Montreal Has Updated Our Knowledge about Melanoma (Cdk12 Is Hyperactivated and a Synthetic-lethal Target In Braf-mutated Melanoma)
9. Recent Research from Federal University of San Francisco Valley Highlight Findings in Apoptosis [bis-nor-diterpene From Cnidoscolus Quercifolius (Euphorbiaceae) Induces Tubulin Depolymerization-mediated Apoptosis In Braf-mutated Melanoma ...]
10. Researchers from Rutgers University Cancer Institute of New Jersey Detail New Studies and Findings in the Area of Melanoma (Complete Response of Brainstem Metastasis In Braf-mutated Melanoma Without Stereotactic Radiosurgery After Initiation of ...)
11. University of Modena and Reggio Emilia Researchers Publish New Data on Melanoma (The Interplay between HGF/c-met Axis and Nox4 in BRAF Mutated Melanoma)
12. New Melanoma Research Reported from University of Warsaw (Tracking of Glycans Structure and Metallomics Profiles in * * BRAF* * Mutated Melanoma Cells Treated with Vemurafenib)
13. MRA Hails FDA Approval of the First Targeted Oral Therapy to Reduce Risk of BRAF-Mutated Melanoma Returning After Surgery
14. MRA Hails FDA Approval of the First Targeted Oral Therapy to Reduce Risk of BRAF-Mutated Melanoma Returning After Surgery
15. Research from Oncology Unit Reveals New Findings on Melanoma (Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma)
16. Reports from Fudan University Highlight Recent Findings in Melanoma (The Role of Autophagy In the Resistance To Braf Inhibition In Braf-mutated Melanoma)
17. Studies from Technical University Update Current Data on Melanoma (Systemic Network Analysis Identifies Xiap and I Kappa B Alpha As Potential Drug Targets In Trail Resistant Braf Mutated Melanoma)
18. Reports Outline Melanoma Findings from F. Janku and Colleagues (Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF -mutated melanoma and other advanced malignancies)
19. Findings from J. McKendrick and Co-Authors Reveals New Information on Melanoma (The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel ...)
20. Research Conducted at University of Alabama Has Updated Our Knowledge about Melanomas (Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells)
21. Data from University of California Advance Knowledge in Melanomas (Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma)
22. Researchers at University of California Report New Data on Melanomas (Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond)
23. Second mutation in BRAF-mutated melanoma doesn't contribute to resistance
24. International Journal of Molecular Sciences Publishes Preclinical Data of Panavance's Misetionamide (GP-2250) in Melanoma
25. Special Report: Biopharma nurtures the next generation of immuno-oncology targets.
26. Genentech Reports Promising Phase II Results with New Targeted Approach in Advanced Melanoma
27. Roche reports promising Phase II results with new targeted approach in advanced melanoma
28. Research Conducted at University Hospitals Cleveland Medical Center Has Updated Our Knowledge about Melanoma (Therapeutic Implications of the Metabolic Changes Associated With Braf Inhibition In Melanoma)
29. Fight against melanoma could use octopus venom as an ally for treatments
30. Patent Application Titled 'Combination Therapies Targeting Mitochondrial Biogenesis For Cancer Therapy' Published Online (USPTO 20240207202)
31. BioAtla Reports Q1 2024 Financial Results and Highlights Recent Progress
32. 8-K: BioAtla, Inc
33. BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
34. Patent Application Titled 'Combined Treatment For Cancer' Published Online (USPTO 20240133870)
35. Research from Seoul National University Hospital in the Area of Pancreatic Cancer Published (Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib)
36. International Journal of Molecular Sciences Publishes Preclinical Data of Panavance's Misetionamide (GP-2250) in Melanoma
37. Metastatic Melanoma Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition 2023 (Updated)
38. Researchers from Netherlands Cancer Institute Provide Details of New Studies and Findings in the Area of Melanoma (The Predictive Value of Fdg Pet/ct for Determining Progression-free Survival In Advanced Stage Iii-iv braf-mutated ...)
39. Research on Melanoma Described by Researchers at Sapienza University of Rome (The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma)
40. Reports Outline Melanoma Research from National Institute of Health (BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers)
41. ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
42. Patent Application Titled 'Combination Therapies Targeting Mitochondrial Biogenesis For Cancer Therapy' Published Online (USPTO 20230181489)
43. Studies from University of Texas Southwestern Medical Center Have Provided New Data on Clinical Oncology (Blebs Promote Cell Survival By Assembling Oncogenic Signalling Hubs)
44. Researchers Submit Patent Application, 'Axl Kinase Inhibitors And Use Of The Same', for Approval (USPTO 20230165857)
45. Researcher at University of Texas MD Anderson Cancer Center Targets Melanoma [Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage ...]
46. Patent Application Titled 'Nmr-Metabolite-Signature For Identifying Cancer Patients Resistant To Cdk4/6 Inhibitors, Endocrine Therapy and Anti-HER2 Therapy' Published Online (USPTO 20230087439)
47. New Melanoma Study Findings Recently Were Reported by Researchers at Charles University of Prague (Prognostic Value of Blood Cell Count-derived Ratios In Braf-mutated Metastatic Melanoma)
48. Skin Cancer Center Researcher Highlights Recent Research in Apoptosis (Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase ...)
49. New Melanoma Research Reported from Kent Oncology Center (Bilateral multifocal central serous retinopathy due to management of metastatic melanoma with BRAF/MEF inhibitors: Case report)
50. University of Zurich Hospital Researchers Describe Findings in Melanoma (P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.